Recent developments across genomics signal a shift in the field’s trajectory. As sequencing, spatial, and multiomic technologies continue to evolve, the focus is moving toward scalability, integration, and real-world application. Codex Insights highlights the trends shaping how genomics may translate into impact in 2026.
More insights in our bi-weekly newsletter.

Each January, JPM sets the tone for the year ahead in biotech and pharma. At JPM 2026, genomics companies delivered steady progress rather than major surprises, with AI remaining a central theme and clinical translation moving further into focus. Codex Insights highlights the key announcements and looks ahead to where the next inflection points for genomics may emerge.
More updates and expert analysis will follow in our blog and newsletter.

Can AI finally help decode the genome’s regulatory code? Variants in noncoding regions drive much of human disease risk, yet their functional interpretation remains a major challenge. Codex Insights explores this question through the perspective of Tuuli Lappalainen, who shares what breakthroughs she’ll be watching for in the year ahead.
The full newsletter features extended analysis and additional expert perspectives.

A new year brings new questions for genomics. As NGS, spatial, and single-cell technologies continue to mature, their impact on research and clinical care is coming into sharper focus. To explore what may define the year ahead, Codex Insights asked leading experts to share their perspectives on the key trends shaping genomics in 2026.
For deeper insights, additional expert voices, and extended analysis, read the full discussion in our newsletter.

In a relatively quiet year for next-generation sequencing, Roche managed to make noise again. Its reveal of a new platform has renewed excitement—and questions. As the field watches for 2026 announcements, the implications could reach far beyond one instrument.